Introduction
Lung cancer is the most frequent cause of cancer deaths in both men and women in USA (Greenlee et al., 2001) . Although tobacco smoking is accepted as the number one cause of this devastating disease, our understanding of the acquired genetic changes leading to lung cancer is still rudimentary. Lung cancer is classified into two major clinic-pathological groups, small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). Squamous cell carcinoma, adenocarcinoma and large cell carcinoma are the major histologic types of NSCLC. As with other epithelial malignancies, lung cancers are believed to arise after a series of progressive pathological changes (preneoplastic lesions) (Colby et al., 1998) . Many of these preneoplastic changes are frequently detected accompanying lung cancers and in the respiratory mucosa of smokers (Colby et al., 1998) . Although many molecular abnormalities have been described in clinically evident lung cancers (Sekido et al., 1998) , relatively little is known about the molecular events preceding the development of lung carcinomas and the underlying genetic basis of tobacco-related lung carcinogenesis.
To investigate the molecular abnormalities involved in the multistep pathogenesis of lung carcinomas we have developed a five-step analysis scheme that included the study of: (a) lung cancer cell lines; (b) microdissected primary lung tumors of the three major histologic types: SCLC, squamous cell carcinoma and adenocarcinoma; (c) respiratory epithelium from patients with lung cancer; (d) respiratory epithelium from smokers without lung cancer and (e) respiratory epithelium from non-smokers.
Under this strategy we systematically search for mutations in tumor cell lines, archival tumor tissues, preneoplastic lesions and normal epithelium (Figure 1) . Recently, we have also analysed genetic changes present in cytologic specimens including sputum samples, bronchial brushes and bronchio-alveolar lavage fluids (BAL) from smokers (Zochbauer-Muller et al., 2001a) . In tissue samples, using a precise microdissection technique (Figure 1 ), under direct microscopic observation a variable number of epithelial cells can be precisely dissected along with invasive primary tumor cells and stromal lymphocytes (as a source of normal constitutional DNA). Using PCRbased techniques, these different specimens are examined for molecular abnormalities (mainly gene mutations, allelic losses, genetic instability, and promoter DNA methylation at genes and chromosomal regions frequently altered in clinically evident lung carcinomas (Figure 1) .
The high risk population targeted for early detection efforts are heavy smokers and patients who have survived of cancer in the upper aerodigestive tract. However, conventional morphologic methods for the identification of premalignant cell populations in the airways have limitations. This has led to a search for other biological properties (including genetic changes) of respiratory mucosa that may provide new methods for assessing the risk of developing invasive lung cancer in smokers, for early detection, and for monitoring their response to chemopreventive regimens.
Overview of molecular abnormalities in lung cancer
Several cytogenetic, allelotyping and comparative genomic hybridization (CGH) studies have revealed that multiple genetic changes are found in clinically evident lung cancers, and involve known and putative recessive oncogenes (tumor suppressor genes, TSG) as well as several dominant oncogenes (Sekido et al., 1998) . Many growth factors or regulatory peptides and their receptors are overexpressed by cancer cells and adjacent normal-appearing cells in the lung, and thus provide a series of autocrine and paracrine growth stimulatory loops in this neoplasm (Viallet and Sausville, 1996) . The list of recessive oncogenes that are involved in lung cancer is likely to include as many as 10 to 15 known and putative genes (Sekido et al., 1998) . These include changes in known TSGs, such as TP53 (17p13), RB (13q14), p16
INK4a (9p21), and new candidate TSG at several chromosomal regions, including the short arm of chromosomes 3 (3p12, DUTT1 gene; 3p14.2, FHIT gene; 3p21, RASFF1 gene; 3p22 -24, BAP-1 gene) (Sekido et al., 1998) . Recessive oncogenes are believed to be inactivated via a two-step process involving both alleles. Knudson (1989) has proposed that the first 'hit' frequently is a point mutation, while the second allele is subsequently inactivated via a chromosomal deletion, translocation, or other event such as methylation of gene promoter regions. In addition to those specific genetic changes, other evidence indicates that genetic instability occurs in lung cancer. This evidence includes changes in the number of short-tandem DNA repeats (also known as microsatellites), frequently present in a wide variety of cancer types, including lung. Overall, 35% (range 0 -76%) of SCLCs and 22% (range 2 -49%) of NSCLCs have shown some evidence of genetic instability at individual loci (Sekido et al., 1998) .
Cell type specific genetic changes in lung cancers
Studies of large numbers of lung cancers have demonstrated different patterns of molecular alterations between the two major groups of lung carcinomas (SCLC and NSCLC) (Virmani et al., 1998) Wistuba et al., 1999a; 2000a,b) . Our results of allelotyping of lung cancer cell lines and microdissected invasive primary tumors indicate that SCLC has more frequent losses at 4p, 4q, 5q21 (APC-MCC region), 10q and 13q14 (RB), while losses at 9p21 and 8p21 -23 are more frequent in NSCLC. Girard et al. (2000) performed a high-resolution genome-wide allelotyping analysis using a similar panel of lung cancer (SCLC and NSCLC) and detected 22 different 'hot spots' for LOH, 13 with a preference for SCLC, seven for NSCLC, and two affecting both. This provides clear evidence on a genome wide scale, that SCLC and NSCLC are different significantly in the TSGs that are inactivated during their pathogenesis. Similarly, the recent findings on the methylation pattern of a number of genes in lung cancer indicate that there are differences between SCLCs and NSCLCs (Burbee et al., 2001; Toyooka et al., 2001; Virmani et al., 2000; Zochbauer-Muller et al., 2001b) .
In addition, we have found different patterns of allelic loss involving the two major types of NSCLC (squamous cell and adenocarcinoma), with higher incidences of deletions at 17p13 (TP53), 13q14 (RB), 9p21 (p16 INK4a ), 8p21 -23 and several 3p regions in squamous cell carcinomas (Wistuba et al., 1999a; 2000a) . These results suggest that more genetic changes accumulate during tumorigenesis in squamous cell carcinomas than in adenocarcinomas. Recently, differences of p16
INK4a , APC and H-cadherin gene methylation frequencies have been detected between squamous cell and adenocarcinoma, suggesting that different gene methylation pattern characterizes the two major histologic types of NSCLC .
Preneoplasia and the development of lung cancer
Lung cancers are believed to arise after a series of progressive pathological changes (preneoplastic or precursor lesions) in the respiratory mucosa ( Figure  2 ). While the sequential preneoplastic changes have been defined for centrally arising squamous carcinomas, they have been poorly documented for large cell carcinomas, adenocarcinomas and SCLCs (Colby et al., 1998) . Mucosal changes in the large airways that may precede or accompany invasive squamous cell carcinoma include hyperplasia (basal cell hyperplasia and goblet cell hyperplasia), squamous metaplasia, squamous dysplasia and carcinoma in situ (Colby et al., 1998) . While hyperplasia and squamous metaplasia are considered reactive and reversible changes, dysplasia and carcinoma in situ are the changes most frequently associated with the development of squamous cell lung carcinomas. Adenocarcinomas may be accompanied by changes including atypical adenomatous hyperplasia (AAH) (Colby et al., 1998) in peripheral airway cells, although the malignant potential of these lesions has not been demonstrated. For SCLC, no specific preneoplastic changes have been described in the respiratory epithelium. Currently available information suggests that lung preneoplastic lesions frequently are extensive and multifocal throughout the lung, indicating a field effect ('field cancerization') by which much of the respiratory epithelium has been mutagenized, presumably from exposure to carcinogens.
Genetic abnormalities in the sequential development of lung cancer
Although our knowledge of the molecular events in invasive lung cancer is relatively extensive, until recently we knew little about the sequence of events in preneoplastic lesions. A few studies have provided suggestions that molecular lesions can be identified at early stages of the pathogenesis of lung cancer. Myc upregulation, cyclin D1 overexpression, p53 protein accumulation, and DNA aneuploidy have been detected in dysplastic epithelium adjacent to invasive lung carcinomas (Betticher et al., 1997; Nuorva et al., 1993; Smith et al., 1996) . K-RAS mutations have been also detected in atypical adenomatous hyperplasias (AAH) (Westra et al., 1993) , which may be a potential precursor lesion of adenocarcinoma. Several molecular changes frequently present in adenocarcinomas are also present in AAH lesions, further evidence that they may represent true preneoplastic lesions (Kitamura et al., 1999) . TP53 gene abnormalities (including mutations, deletions and over-expression) have been demonstrated in non-malignant epithelium of lung specimens obtained from lung cancer patients (Ahrendt et al., 1999; Lang et al., 2000; Sundaresan et al., 1992) . Franklin et al. (1997) described an identical TP53 gene mutation widely dispersed in normal and preneoplastic epithelium of a smoker without lung cancer. Our recent studies allowed us to identify some of the genetic changes involved in the pathogenesis of lung cancer (Table 1) . Because the preneoplastic changes have been well established only for squamous cell carcinoma of the lung, most of our findings are referred to this histologic type of lung cancer (Figure 3 ).
Mutations follow a sequence
Our data have demonstrated that in lung cancer the developmental sequence of molecular changes is not random, with allelic loss at one or more 3p regions (especially telomeric regions 3p21, 3p22 -24 and 3p25) and 9p21, and to a lesser extent at 8p21 -23, 13q14 (RB) and 17p13 (TP53), being detected frequently very early in pathogenesis (histologically normal epithelium) (Wistuba et al., 1999a,b; 2000a) . In contrast, LOH at 5q21 (APC-MCC region) and K-RAS mutations were only detected at the carcinoma in situ stage, and TP53 mutations appear at variable times. Detailed examination of all our material suggests that the order of events (allelic losses) is usually either 3p?9p?8p or 3p?8p?9p deletions followed by TP53 deletions (Wistuba et al., 1999a) . In early lesions (normal epithelium-metaplasia), the 3p losses are small and multifocal, commencing at the central (3p21) and telomeric end of the chromosomal arm (Wistuba et al., 2000a) . In later lesions (carcinoma in situ and invasive cancers), all or almost the entire chromosome is lost. Similar findings were detected by chromosome 8p analysis (Wistuba et al., 1999a) .
Sequential vs parallel theory of lung cancer development
The development of epithelial cancers requires multiple mutations stepwise accumulation of which may represent a mutator phenotype. Thus, it is possible that those preneoplastic lesions that have accumulated multiple mutations are at higher risk Figure 2 Histopathologic and molecular changes during the pathogenesis of lung cancer. Sequential changes are involved in the development of NSCLC, squamous cell and adenocarcinoma (sequential theory of cancer development). SCLC may arise directly from histologically normal or from mildly abnormal epithelium, without passing through the entire histologic sequence (parallel theory of cancer development). CIS, carcinoma in situ; AAH, atypical adenomatous hyperplasia; BAC, bronchioalveolar carcinoma (non-invasive adenocarcinoma) for progression to invasive cancer. Of interest, using a panel of microsatellite markers targeting chromosomal regions frequently deleted in invasive lung carcinomas, we have detected similar incidences of allelic loss between histologically normal epithelium and slightly abnormal epithelial changes (hyperplasia and squamous metaplasia) accompanying lung carcinomas (Wistuba et al., 1999b) . However, high grade dysplasias and carcinoma in situ accompanying invasive squamous cell lung carcinomas demonstrated a significant increase of total number of allelic losses (Wistuba et al., 1999b) , suggesting that the accumulation of mutations correlates with the morphologic changes and may lead to development of invasive carcinomas (sequential theory of lung cancer development) (Figures 2 and 3 ). These lesions usually persist after smoking cessation (Lam et al., 1999) . In our study (Wistuba et al., 2000b) comparing allelic loss and genetic instability frequency in cell types of lung cancer and their accompanying bronchial epithelia, SCLCs demonstrated a significantly higher incidence of genetic abnormalities than NSCLC tumor types. Our findings indicated that more widespread and more extensive genetic damage is present in bronchial epithelium in patients with SCLC. The finding that some specimens of normal or mildly abnormal epithelia accompanying SCLCs have a very high incidence of genetic changes (Wistuba et al., 2000b) , suggests that SCLC may arise directly from histologically normal or from mildly abnormal epithelium, without passing through the entire histologic sequence (parallel theory of cancer development) (Figure 2 ).
In addition, the very low frequency of molecular abnormalities in the centrally located bronchial respiratory epithelium in patients with resected peripheral lung adenocarcinomas, compared to those specimens from patients with squamous cell carcinomas and SCLC, suggests the presence of two compartments with differences in the smoking-related genetic damage effect in the lung. Thus, smokers who develop squamous cell carcinoma and SCLC have more smoking related genetic damage in the respiratory epithelium of the central airway, while in patients who develop adenocarcinoma the damage mainly in the peripheral airways (bronchioles and alveoli). Our recent preliminary results in the genetic damage mapping of the central and peripheral lung airway from patients with centrally located squamous cell carcinomas and peripheral adenocarcinomas of the lung confirm this theory (Wistuba et al., data not published).
Allele specific mutations
We have noted that the specific parental allelic lost in chromosomal deletions present in preneoplastic lesions and their accompanying cancers are similar (Hung et al., 1995; Kishimoto et al., 1995; Wistuba et al., 1999b) . We have referred to this phenomenon as allele specific mutations (ASM). We have detected ASMs in preneoplastic lesions located in all regions of the respiratory epithelium and in a wide spectrum of preneoplastic lesions, including hyperplasia, squamous metaplasia, dysplasia and carcinoma in situ (Hung et al., 1995; Kishimoto et al., 1995; Wistuba et al., 1999b) . Of great interest, we have detected ASMs in smoking related damaged epithelium, even in biopsy samples obtained from different lungs . Although the mechanism by which this phenomenon occurs is unknown, ASM is likely to be a phenomenon of major biological significance. 
Size of the patches with genetic changes in the pathogenesis of lung cancer
Almost all of the current chemoprevention studies in the USA utilize serial bronchoscopic biopsies to evaluate response. While histopathological evaluation is the 'gold standard', many studies utilize molecular or other biological endpoints. For these reasons, we undertook an evaluation of the size and frequency of the molecularly altered (allelic loss and microsatellite alterations) clonal patches in smoking damaged bronchial epithelium. Our findings indicated that multiple small clonal and subclonal patches of molecular abnormalities (not much larger in size than the average bronchial biopsy obtained by fluorescence bronchoscopy) can be detected in the normal and slightly abnormal bronchial epithelium of patients with lung cancer (Park et al., 1999) . The clonal patches of bronchial epithelium having molecular changes were usually small, and they were estimated to be approximately 40 000 to 360 000 cells. Based on the size of the average biopsy obtained by fluorescence bronchoscopy, we estimated the average surface area of the clonally altered patches to be between 4 and 80 mm 2 . Thus, we estimate that there may be eight or more independent molecularly altered clonal patches per cm 2 . These findings are consistent with the findings of Hittelman (1999) who found evidence for the presence of numerous small monosomic and trisomic clonal and subclonal patches in smoking damaged upper aerodigestive epithelium as determined by FISH analyses. All these findings suggest that the process of obtaining a biopsy may result in 'spontaneous' reversion of molecularly altered foci of bronchial epithelium to normal. Thus, our recent findings may help in the design of chemoprevention studies utilizing sequential bronchial biopsies for the monitoring of intermediate biomarkers as endpoints.
Aberrant methylation in the pathogenesis of lung cancer
Aberrant methylation of CpG rich areas ('CpG islands') present in the promoter regions of approximately half of all human genes is the major mechanism of silencing tumor suppressor genes . Each tumor, including lung cancers, have a specific pattern of methylation . We have described differences in the methylation patterns of SCLC, NSCLC and bronchial carcinoids Zochbauer-Muller et al., 2001a) . One of the genes frequently silenced by methylation (as well as by other mechanisms) is the p16
INK4a gene. The finding of p16
INK4a methylation in the early stages of progression of squamous cell lung carcinoma of the lung support the critical role for this molecular change (Belinsky et al., 1998) . p16
INK4a methylation has been detected in 75% of carcinoma in situ adjacent to squamous cell carcinomas and the frequency of this event increased during disease progression from basal cell hyperplasia (17%) to squamous metaplasia (24%) to carcinoma in situ lesions (50%). Recently, aberrant methylation of the p16
INK4a and/or O 6 -methyl-guanine-DNA methyltransferase promoters have been detected in DNA from sputum in 100% of patients with squamous cell lung carcinoma up to 3 years before clinical diagnosis (Palmisano et al., 2000) . Although more studies need to be performed in lung cancer preneoplastic lesions, the recent findings suggest that aberrant gene methylation can be an early event in lung cancer and may constitute in this neoplasm new marker for risk assessment, early detection and monitoring of chemoprevention trials (Soria et al., 2002) .
Telomerase dysregulation in the pathogenesis of lung cancer
Telomerase is currently recognized as a nearly ubiquitous tumor marker. Telomerase is a specialized ribonucleoprotein polymerase that adds TTAGGG repeats at the ends of vertebrate chromosomal DNA called telomeres (Morin, 1989) . Human telomeres undergo progressive shortening with cell division through replication of dependent sequence loss at DNA termini (Hastie et al., 1990) . Telomerase is thought to compensate for the loss of telomeric repeats and is associated with the acquisition of the immortal phenotype. Activation of telomerase is nearly universal in lung and other cancers (Hiyama et al., 1995) , and is regarded as one of the hallmarks of cancer (Hanahan, 2000) . In NSCLC, the telomerase positive percentage is 73% with weak to moderate activities whereas 100% of SCLC are positive and show strong signal activities (Hiyama et al., 1995) .
Telomerase has been detected in preinvasive lesions in a number of tumor systems, including lung (Yashima et al., 1997) . In lung, low levels of telomerase activity have been detected in hyperplasia, dysplasia and CIS compared to invasive cancer. While weak telomerase RNA expression is detected in basal layers of normal and hyperplastic epithelium from lung cancer patients, dysregulation of telomerase expression increases with tumor progression with moderate to strong expression throughout the multilayers of the epithelium in metaplasia, dysplasia and CIS (Yashima et al., 1997) .
Smoking damaged bronchial epithelium
After smoking cessation, the risk of developing lung cancer decreases, but never reaches baselines levels of never smokers (Peto et al., 2000) . It has been established that advanced lung preneoplastic changes occur more frequently in smokers than in nonsmokers and increase in frequency with amount smoking, adjusted by age. After smoking cessation, metaplastic and mild dysplastic changes frequently regress, while moderate to severe dysplastic changes persist (Lam et al., 1999) . Changes in bronchial epithelium, including metaplasia and dysplasia, have been utilized as surrogate end points for chemopre-vention studies. Risk factors that identify normal and premalignant bronchial tissue at increased risk for malignant progression need to be better defined. However, only scant information is available about molecular changes in the respiratory epithelium of smokers without cancer.
Two independent studies showed that the genetic changes (loss of heterozygosity and microsatellite alterations) found in invasive cancers and preneoplasia can also be identified in morphologically normal appearing bronchial epithelium from current or former smokers and may persist for many years after smoking cessation (Mao et al., 1997; Wistuba et al., 1997) (Figure 4) . In general, such genetic changes are not found in the bronchial epithelium from true, lifetime never smokers. In one study 86% of the individuals who smoked demonstrated LOH in one or more biopsies and 24% showed LOH in all biopsies. Somewhat surprisingly, about half of the histologically normal epithelium showed LOH; however, the frequency of LOH and the severity of histologic changes did not correspond until the carcinoma in situ stage. As it has been observed in epithelial foci accompanying invasive lung carcinoma (Wistuba et al., 1999b) , allelic losses on chromosomes 3p and 9p were more frequent than deletions in chromosomes 5q21, 17p13 (TP53 gene) and 13q14 (RB gene). All of these findings support the hypothesis that identifying biopsies with extensive or certain patterns of allelic loss may provide new methods for assessing the risk in smokers of developing invasive lung cancer and for monitoring response to chemoprevention.
Preliminary results on methylation analysis of several genes, including RARb, H-cadherin, APC, p16
INK4a and RASFF1 indicate that abnormal gene methylation is a relatively frequent (at least one gene, 35%) in oropharyngeal and bronchial epithelial cells in heavy smokers with evidence of sputum atypia (ZochbauerMuller et al., in preparation) . FHIT gene methylation was detected in 37% of primary NSCLCs, 9% of the corresponding nonmalignant lung tissues and in 17% of bronchial brushes from heavy cigarette smokers (Zochbauer-Muller et al., in preparation) . These findings indicate that methylation analysis of gene promoter regions may be a useful marker for the risk assessment of lung cancer in smoker individuals. In an independent study, one of the authors (L Mao) has demonstrated methylation of one or more of three genes tested in about one third of smoker subjects (Soria et al., 2002) . Dysregulation in telomerase expression has been also noted in bronchoscopic biopsies of smoking damaged epithelium of current and former smokers, suggesting that telomerase could be also used as a potential marker for risk assessment (Rahti et al., unpublished data) . Recently, Soria et al. (2001) analysed the expression of the human telomerase reverse transcriptase catalytic subunit (hTERT) by RNA in situ hybridization in bronchial biopsy specimens from cigarette smokers who were enrolled in a randomized, double-blinded, placebo-controlled chemoprevention trial of N-(4-hydroxyphenyl)retinamide (4-HPR). They demonstrated that telomerase is frequently reactivated in the lungs of cigarette smokers and this activation could be modulated by the chemopreventive agent. Thus, hTERT expression is a promising potential biomarker for risk assessment and for the evaluation of the efficacy of chemopreventive agents in lung carcinogenesis. Figure 4 Left, loss of heterozygosity (LOH) frequencies by samples and subjects in bronchoscopy biopsies obtained from smokers and non-smokers (Mao et al., 1997; Wistuba et al., 1997) . LOH is expressed as frequency at any chromosomal loci examined. Right, representative autoradiographs of microsatellite analyses for LOH at chromosome 3p21 region in bronchoscopy biopsies from nonsmoker and smoker. Asterisks indicate LOH. L, lymphocytes (as source of constitutional DNA); N, histologically normal epithelium; H, hyperplasia; D, dysplasia We demonstrated that molecular changes (allelic loss and genomic instability) in the bronchial epithelium may persist long after smoking cessation Mao et al., 1997) . Recently, Lee et al. (2001) demonstrated that smoking appears to elicit a doserelated proliferative response in the bronchial epithelia of active smokers measured by the Ki-67 proliferation index. Although the proliferative response decreased gradually in former smokers, a subset of individuals had detectable proliferation for many years after quitting smoke. Thus, bronchial epithelial proliferation, measured by Ki-67, may provide a useful biomarker in the assessment of lung cancer risk and in the response to chemopreventive interventions ).
Molecular markers for early detection of lung cancer
Mutant K-RAS and TP53 genes have been detected in the sputum some months prior to diagnosis of cancer (Mao et al., 1994) and K-RAS mutations have been detected in bronchioalveolar lavage fluids from patients with adenocarcinoma (56%), but not in patients with squamous cell carcinoma or with other diagnosis (Mills et al., 1995) . Ahrendt et al. (1999) have reported that molecular assays could identify cancer cells in bronchioalveolar lavage fluid from patients with early-stage lung cancers. Using PCR-based assays for K-RAS and TP53 gene mutations, CpG-island methylation of the p16
INK4a gene and for microsatellite instability, they were able to detect identical molecular abnormalities in the bronchioalveolar fluid and corresponding tumors in 23 of 43 (53%) of the cases. These findings suggest that molecular strategies may detect the presence of neoplastic cells in the central and peripheral airways in patients with early-stage lung carcinomas.
As we stated above, several genes important in lung tumorigenesis are methylated in lung cancers, and the list may increase with recent extensive research activities. Aberrant methylation commences during the multistage pathogenesis, in bronchial epithelium with mildly abnormal changes (hyperplasia/squamous metaplasia) (Belinsky et al., 1998) . Because methylated DNA sequences can be detected even when they represent a small fraction within total normal DNA, they are very attractive candidate biomarkers for early molecular detection and monitoring chemoprevention studies. The potential of using assays for aberrant p16
INK4a methylation to identify disease and/or risk was suggested by detection of this change in sputum from a small series of patients with cancer and smoker individual without lung cancer (Belinsky et al., 1998) . Recently, abnormal methylation of the FHIT gene has been shown in bronchial brushes from heavy smokers (17%) (Zochbauer-Muller et al., 2001a) . Thus, aberrant methylation may be useful for early detection, risk assessment and for monitoring the efficacy of chemoprevention trials.
Recently, Kersting et al. (2000) reported that p16
INK4a promoter hypermethylation and TP53 mutations can occur in chronic smokers before any clinical evidence of neoplasia and may be indicative of an increased risk of developing lung cancer or of early disease. In contrast, K-RAS mutations occur exclusively in the presence of clinically detectable neoplastic transformation. Thus, molecular analysis of sputum for such markers may provide an effective means of screening chronic smokers to enable earlier detection and therapeutic intervention of lung cancer.
